trifluoperazine has been researched along with Glioblastoma in 15 studies
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion." | 7.96 | The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. ( Alli, C; Bhat, K; Cheng, F; Cloughesy, TF; Damoiseaux, R; Duhachek-Muggy, S; He, L; Kornblum, HI; Liau, LM; Medina, P; Nghiemphu, PL; Pajonk, F; Pellegrini, M; Saki, M; Vlashi, E; Yu, G; Zemke, NR, 2020) |
| "Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested." | 7.88 | Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. ( Elkamhawy, A; Hassan, AHE; Hong, J; Jeon, B; Kang, S; Kang, SS; Lee, CJ; Lee, JM; Oh, SJ; Paek, SH; Paik, S; Roh, EJ, 2018) |
| " We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion." | 3.96 | The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. ( Alli, C; Bhat, K; Cheng, F; Cloughesy, TF; Damoiseaux, R; Duhachek-Muggy, S; He, L; Kornblum, HI; Liau, LM; Medina, P; Nghiemphu, PL; Pajonk, F; Pellegrini, M; Saki, M; Vlashi, E; Yu, G; Zemke, NR, 2020) |
| "Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested." | 3.88 | Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. ( Elkamhawy, A; Hassan, AHE; Hong, J; Jeon, B; Kang, S; Kang, SS; Lee, CJ; Lee, JM; Oh, SJ; Paek, SH; Paik, S; Roh, EJ, 2018) |
| "Glioblastoma multiforme is a fatal malignancy of the central nervous system, demanding new methods of treatment." | 2.67 | The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. ( Byrne, TN; Choudhury, S; Davis, CA; Durivage, HJ; Gates, JA; Hait, WN; Piepmeier, J, 1990) |
| "1." | 1.30 | Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents. ( Crumb, WJ; Murawsky, MK; Rampe, D; Wible, B, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Yu, J | 1 |
| Pan, H | 1 |
| Hu, P | 1 |
| Hao, Y | 1 |
| Cai, W | 1 |
| Zhu, H | 1 |
| Yu, AD | 1 |
| Xie, X | 1 |
| Ma, D | 1 |
| Yuan, J | 1 |
| Kang, S | 4 |
| Lee, JM | 2 |
| Jeon, B | 2 |
| Elkamhawy, A | 1 |
| Paik, S | 1 |
| Hong, J | 2 |
| Oh, SJ | 1 |
| Paek, SH | 2 |
| Lee, CJ | 2 |
| Hassan, AHE | 1 |
| Kang, SS | 2 |
| Roh, EJ | 2 |
| Fernandes, GFDS | 1 |
| Fernandes, BC | 1 |
| Valente, V | 1 |
| Dos Santos, JL | 1 |
| Stringer, BW | 1 |
| De Silva, MI | 1 |
| Greenberg, Z | 1 |
| Noreña Puerta, A | 1 |
| Adams, R | 1 |
| Milky, B | 1 |
| Zabolocki, M | 1 |
| van den Hurk, M | 1 |
| Ebert, LM | 1 |
| Fairly Bishop, C | 1 |
| Conn, SJ | 1 |
| Kichenadasse, G | 1 |
| Michael, MZ | 1 |
| Ormsby, RJ | 1 |
| Poonoose, S | 1 |
| Bardy, C | 1 |
| Kwon, HN | 1 |
| Park, S | 1 |
| Bhat, K | 1 |
| Saki, M | 1 |
| Vlashi, E | 1 |
| Cheng, F | 1 |
| Duhachek-Muggy, S | 1 |
| Alli, C | 1 |
| Yu, G | 1 |
| Medina, P | 1 |
| He, L | 1 |
| Damoiseaux, R | 1 |
| Pellegrini, M | 1 |
| Zemke, NR | 1 |
| Nghiemphu, PL | 1 |
| Cloughesy, TF | 1 |
| Liau, LM | 1 |
| Kornblum, HI | 1 |
| Pajonk, F | 1 |
| Zhang, X | 1 |
| Xu, R | 1 |
| Zhang, C | 1 |
| Xu, Y | 1 |
| Han, M | 1 |
| Huang, B | 1 |
| Chen, A | 1 |
| Qiu, C | 1 |
| Thorsen, F | 1 |
| Prestegarden, L | 1 |
| Bjerkvig, R | 1 |
| Wang, J | 1 |
| Li, X | 1 |
| Pinheiro, T | 2 |
| Otrocka, M | 2 |
| Seashore-Ludlow, B | 2 |
| Rraklli, V | 2 |
| Holmberg, J | 2 |
| Forsberg-Nilsson, K | 2 |
| Simon, A | 2 |
| Kirkham, M | 2 |
| Ramis, G | 1 |
| Villalonga-Planells, R | 1 |
| Serra-Sitjar, M | 1 |
| Brell, M | 1 |
| Fernández de Mattos, S | 1 |
| Villalonga, P | 1 |
| Moon, HE | 1 |
| Choi, J | 1 |
| Yoon, NA | 1 |
| Cheng, EH | 1 |
| Gorelick, FS | 1 |
| Czernik, AJ | 1 |
| Bagaglio, DM | 1 |
| Hait, WN | 2 |
| Wible, B | 1 |
| Murawsky, MK | 1 |
| Crumb, WJ | 1 |
| Rampe, D | 1 |
| Annabi, B | 1 |
| Pilorget, A | 1 |
| Bousquet-Gagnon, N | 1 |
| Gingras, D | 1 |
| Béliveau, R | 1 |
| Byrne, TN | 1 |
| Piepmeier, J | 1 |
| Durivage, HJ | 1 |
| Choudhury, S | 1 |
| Davis, CA | 1 |
| Gates, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme[NCT04224441] | Phase 2 | 41 participants (Anticipated) | Interventional | 2019-12-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for trifluoperazine and Glioblastoma
| Article | Year |
|---|---|
Recent advances in the discovery of small molecules targeting glioblastoma.
Topics: Animals; Central Nervous System Neoplasms; Drug Discovery; Glioblastoma; Humans; Neoplastic Stem Cel | 2019 |
1 trial available for trifluoperazine and Glioblastoma
| Article | Year |
|---|---|
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Calmodulin; | 1990 |
13 other studies available for trifluoperazine and Glioblastoma
| Article | Year |
|---|---|
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
Topics: Autophagy; Calcium Channel Blockers; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluspirilene; G | 2007 |
Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents.
Topics: Animals; Antineoplastic Agents; Antipsychotic Agents; Brain; Brain Neoplasms; Calcium; Cell Line, Tu | 2018 |
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Glioblastoma; Humans; Temozolomide; Trifluoper | 2023 |
Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Topics: Amino Acid Sequence; Binding Sites; Brain Neoplasms; Calmodulin; Cell Line, Tumor; Cell Movement; Ce | 2020 |
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
Topics: Animals; beta Catenin; Brain Neoplasms; Disease Models, Animal; Dopamine Antagonists; Gene Expressio | 2020 |
Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination.
Topics: Animals; Autophagy; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Homologo | 2017 |
A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dopamine Antagonists; Do | 2017 |
Reprint of: A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth.
Topics: Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dopamine; Dose-Response Relationshi | 2018 |
The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; ErbB Receptors; Erlotinib Hydro | 2019 |
Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R.
Topics: Animals; Antineoplastic Agents; Calcium; Calmodulin; Cell Line, Tumor; Cell Movement; Cell Survival; | 2017 |
Calmodulin-dependent protein kinases in rat glioblastoma.
Topics: Animals; Brain Neoplasms; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Calmodulin; Gliobla | 1995 |
Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Cloning, Molecular; Female; Fluspirilene; Gene Expre | 1997 |
Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells.
Topics: Amino Acid Sequence; Animals; Base Sequence; Calmodulin; COS Cells; DNA, Complementary; Enzyme Activ | 2001 |